Sign In
Buy BPMC
$129.46
+0 (+0%)
At Close: Oct 17, 2025
Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates
09:06am, Wednesday, 17'th Feb 2021
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 2.55% and -1.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Recap: Blueprint Medicines Q4 Earnings
07:36am, Wednesday, 17'th Feb 2021
Shares of Blueprint Medicines (NASDAQ:BPMC) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share fell 13.33% over the past year to ($1.53), which beat the estimat
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic
12:02pm, Wednesday, 13'th Jan 2021
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic
Blueprint Medicines Announces R&D Leadership Transitions
08:05am, Monday, 11'th Jan 2021
CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced leadership transitions for the company's research and development organization. Effective
3 Biotech Stocks Worth Adding to Your Portfolio in 2021
09:47am, Friday, 08'th Jan 2021
We highlight a few biotech companies, which outperformed the sector in 2020 and are likely to witness a winning run in the near term.
Blueprint Medicines (BPMC) Rises 40% in Past 3 Months: Here's Why
03:03pm, Monday, 21'st Dec 2020
Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's second drug, Gavreto, gets approved for two types of cancer indications.
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Friday, 04'th Dec 2020
CAMBRIDGE, Mass., Dec. 4, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherap
CAMBRIDGE, Mass., Dec. 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherap
5 Under-the-Radar Tickers That Will Stomp the Market in 2021
06:32am, Thursday, 19'th Nov 2020
Investors are hyper-focused on COVID-19 right now, but once vaccines for the virus have been approved, other healthcare stocks will start to zoom forward.
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q3 2020 Results - Earnings Call Transcript
02:52pm, Thursday, 29'th Oct 2020
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q3 2020 Results - Earnings Call Transcript
5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month)
05:28pm, Monday, 26'th Oct 2020
Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry expertise i
Radisson Blu has a new story to tell in Toronto
04:01am, Wednesday, 16'th Sep 2020
The upscale hotel model is upping the ante for elegance in Canada (Sponsor Content)
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2020 Update
10:49am, Friday, 11'th Sep 2020
Halvorsen's 13F portfolio value increased from $19.21B to $23.14B. The number of positions increased from 64 to 71.
Blueprint Receives FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma
02:05am, Thursday, 10'th Sep 2020
FDA approves Blueprint’s GAVRETO for lung cancer. Regeneron reports positive data for Dupixent.
Blueprint Medicines Corp (NASDAQ:BPMC) Receives $95.90 Consensus Target Price from Analysts
07:14am, Saturday, 22'nd Aug 2020
Shares of Blueprint Medicines Corp (NASDAQ:BPMC) have earned an average recommendation of “Buy” from the sixteen analysts that are currently covering the stock, MarketBeat Ratings reports. One inv
